Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-FiLAR: Levamisole for Loiasis
NCT06252961Phase 3Recruiting
- Sponsor
- Programme National de Lutte contre l'Onchocercose
- Start
- Jun 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levamisole in loiasis (3 arms), sponsored by Programme National de Lutte contre l'Onchocercose. Primary endpoint: Tolerance of multiple doses of levamisole at 2 weeks. Started Jun 2024; status: recruiting.
02
Drugs
levamisole
03
Conditions
loiasis
Beyond the preview
Go deeper on NCT06252961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252961.